Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 160.09m |
Free float | 153.08m |
P/E (TTM) | -- |
Market cap | 2.18bn USD |
EPS (TTM) | -2.76 USD |
--
More ▼
Press releases
- Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
- Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.
- Novavax to Participate in Upcoming September Conferences
- Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
- Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
- Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024
More ▼